



Cystic Fibrosis Agents (Oral)

Please fax this completed form to (833) 645-2734 OR mail to: Pharmacy Services | 5 River Park Place East, Suite 210 | Fresno, CA 93720. You can also complete online at CoverMyMeds.com.

Date of request:	Reference #:	MAS:							
Patient	Date of birth	ProviderOne ID or Coordinated Care ID							
Pharmacy name	Pharmacy NPI	Telephone number	Fax number						
Prescriber	Prescriber NPI	Telephone number	Fax number						
Medication and strength		Directions for use	Qty/Days supply						
<p>1. Is this request for a continuation of existing therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, is there documentation showing any of the following? (check all that apply)</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 50%;"><input type="checkbox"/> Improvement in FEV1</td> <td style="width: 50%;"><input type="checkbox"/> Decrease in the decline of lung function</td> </tr> <tr> <td><input type="checkbox"/> Decreased pulmonary exacerbations or infections</td> <td><input type="checkbox"/> Decreased hospitalizations</td> </tr> <tr> <td><input type="checkbox"/> Increased weight or growth</td> <td></td> </tr> </table> <p>2. Indicate patient's diagnosis: <input type="checkbox"/> Cystic Fibrosis <input type="checkbox"/> Other. Specify:</p> <p>3. Will the patient be taking the requested medication simultaneously with a CYP3A4 inducer? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, what CYP3A4 inducer patient will be taking?</p> <p>4. Does patient have any of the following (check all that apply): <input type="checkbox"/> At least one mutation in the CFTR gene that is responsive to ivacaftor (Kalydeco), tezacaftor/ivacaftor (Symdeko), or or elexacaftor/tezacaftor/ivacaftor (Trikafta) <input type="checkbox"/> At least one F508del CFTR mutation for elexacaftor/tezacaftor/ivacaftor (Trikafta) <input type="checkbox"/> Homozygous F508del CFTR mutation (2 copies) for lumacaftor/ivacaftor (Orkambi) or tezacaftor/ivacaftor (Symdeko)</p> <p>5. Does patient have severe hepatic insufficiency (Child-Pugh class C)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>6. For pediatric patients under 18 years of age: Was there a baseline ophthalmic examination performed to monitor lens opacities/cataracts? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>7. Is this prescribed by or in consultation with a provider who specializes in the treatment of cystic fibrosis? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>				<input type="checkbox"/> Improvement in FEV1	<input type="checkbox"/> Decrease in the decline of lung function	<input type="checkbox"/> Decreased pulmonary exacerbations or infections	<input type="checkbox"/> Decreased hospitalizations	<input type="checkbox"/> Increased weight or growth	
<input type="checkbox"/> Improvement in FEV1	<input type="checkbox"/> Decrease in the decline of lung function								
<input type="checkbox"/> Decreased pulmonary exacerbations or infections	<input type="checkbox"/> Decreased hospitalizations								
<input type="checkbox"/> Increased weight or growth									
CHART NOTES, CFTR GENE MUTATION TESTING AND LABS ARE REQUIRED WITH THIS REQUEST									
Prescriber signature	Prescriber specialty	Date							

Pharmacy Services will respond via fax or phone within 24 hours of receipt of the request. Requests for prior authorization must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)